Findings of a recent small trial a six-week regimen of Harvoni cured all acute hepatitis C infections in HIV positive people who had hepatitis C viral loads below 7 million were presented at CROI 2016 in Boston.
The study was conducted with 26 HIV positive individuals recently infected with Hepatitis C. Two thirds of participants had genotype 1a and the remaining third had genotype 4. Participants were either on HIV treatment with a suppressed viral load or not on antiretrovirals with no plans to start them. The most common HIV regimens were efavirenz (Sustiva), raltegravir (Isentress), dolutegravir (Tivicay), ritonavir (Norvir) boosted atazanavir (Reyataz) and tenofovir/emtricitabine (Truvada).
77% (20) of the participants achieved a sustained virologic response 12 weeks after completing therapy, which is considered a cure. 15% (4) experienced virologic failure including 3 who relapsed and 1 who was reinfected with a different hepatitis C genotype. Two participants were lost to follow-up. All participants who relapsed had a hepatitis C viral load > 7 million.
The webcast of the presentation can be seen HERE
Read the conference abstract HERE